Inflammatory bowel disease registry for adults on biologics or JAKs
Part of Digestive system clinical trials.
This study is a real-world registry that collects information about people with Crohn’s disease or ulcerative colitis who take certain medicines (biologics or tofacitinib). It helps researchers better understand how these treatments are used and how people are doing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Give written consent to join the registry
- Be able to share personal details like your name, birth date, sex, and home ZIP code
- Have a Crohn’s disease or ulcerative colitis diagnosis confirmed by a gastroenterologist
- Currently use, or be starting, an approved biologic medicine or tofacitinib (for UC or Crohn’s)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks people with known or suspected inflammatory bowel disease to enroll in a registry and biorepository. It helps researchers better understand the condition using health information and stored biological samples.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This study looks at what factors help predict how inflammatory bowel disease (IBD) may progress over time. You may be able to join if you are an adult with IBD and fit one of the study groups based on whether you have used TNF-blocking medicines before.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study follows adults with moderate-to-severe Crohn's disease or ulcerative colitis who are starting treatment with guselkumab (Tremfya). It aims to see how well the medication works and how long the effects last over time.
This study gathers health information from people with inflammatory bowel disease (IBD) and others to build a database. It may help doctors better understand and treat these conditions in the future.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.